BRAINCURE for BPAN starts today.

Vicente Guzmán (Rector UPO) y Antonio López (Presidente ENACH Asociación)

A group of families from different countries reopens the BRAINCURE for BPAN research line.

In an unprecedented action, a group of families at international level and coordinated by ENACH Association, have launched a specific line of research for the subtype NEURODEGENERATION ASSOCIATED WITH PROTEIN BETA-PROPELLER (BPAN).
ENACH Asociación is a promoter of the BRAINCURE Project, whose mission is to look for already existing drugs on the market approved by the FDA and the EMA that, combined with each other and in different doses, can be a therapeutic option for the ENACH patients of THIS GENERATION.

The promising results obtained in the laboratory with cellular models of the patients themselves, which later have been transferred to the clinic in an equally successful manner in the ENACH subtype called PKAN (the most prevalent of the subtypes) has led to applying the same methodology to other subtypes ENACH with encouraging results at the laboratory level.

It is personalized medicine in which it is investigated directly with skin cells of the patients themselves, which are reprogrammed to neurons. For this, families have sent cell samples of their children affected by BPAN, with which they will work individually, to find potential therapeutic options that can be applied to those same patients immediately after the approval of their neuropediatrician.

At the head of the BRAINCURE project is Professor José Antonio Sánchez Alcázar of the Department of Physiology, Anatomy and Cell Biology at the Pablo de Olavide University in Seville, Spain.

Esta web utiliza cookies propias y de terceros para su correcto funcionamiento y para fines analíticos. Al hacer clic en el botón Aceptar, aceptas el uso de estas tecnologías y el procesamiento de tus datos para estos propósitos. Más información
Privacidad